Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013

Article  PubMed  CAS  Google Scholar 

Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M (2023) Targeting DNA damage response pathways in cancer. Nat Rev Cancer 23(2):78–94. https://doi.org/10.1038/s41568-022-00535-5

Article  PubMed  CAS  Google Scholar 

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921. https://doi.org/10.1038/nature03445

Article  PubMed  CAS  Google Scholar 

Goel N, Foxall ME, Scalise CB, Wall JA, Arend RC (2021) Strategies in overcoming homologous recombination proficiency and PARP inhibitor resistance. Mol Cancer Ther 20(9):1542–1549. https://doi.org/10.1158/1535-7163.MCT-20-0992

Article  PubMed  PubMed Central  CAS  Google Scholar 

Drean A, Lord CJ, Ashworth A (2016) PARP inhibitor combination therapy. Crit Rev Oncol Hematol 108:73–85. https://doi.org/10.1016/j.critrevonc.2016.10.010

Article  PubMed  Google Scholar 

Lopez JS, Banerji U (2017) Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol 14(1):57–66. https://doi.org/10.1038/nrclinonc.2016.96

Article  PubMed  CAS  Google Scholar 

Smith HL, Willmore E, Mukhopadhyay A, Drew Y, Curtin NJ (2022) Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling. Cancers (Basel). https://doi.org/10.3390/cancers14225559

Article  PubMed  PubMed Central  Google Scholar 

Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G (2012) A phase I combination study of Olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 18(8):2344–2351. https://doi.org/10.1158/1078-0432.CCR-11-2425

Article  PubMed  PubMed Central  CAS  Google Scholar 

Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M (2016) A randomized phase I/II study of ABT-888 in combination with Temozolomide in recurrent Temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol 126(2):309–316. https://doi.org/10.1007/s11060-015-1966-z

Article  PubMed  CAS  Google Scholar 

van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, de Bono JS, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Greve J, Schellens JHM (2020) Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Invest New Drugs 38(4):1096–1107. https://doi.org/10.1007/s10637-019-00857-6

Article  PubMed  CAS  Google Scholar 

van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, de Bono JS, Schellens JHM (2020) Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). Invest New Drugs 38(4):1117–1128. https://doi.org/10.1007/s10637-019-00856-7

Article  PubMed  CAS  Google Scholar 

Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H (2022) Review: role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making. Pharm Res 39(8):1669–1680. https://doi.org/10.1007/s11095-022-03288-w

Article  PubMed  PubMed Central  CAS  Google Scholar 

FDA (2024) Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases. Guidance for Industry

Bachmann F, Koch G, Bauer RJ, Steffens B, Szinnai G, Pfister M, Schropp J (2024) Computing optimal drug dosing regarding efficacy and safety: the enhanced optidose method in NONMEM. J Pharmacokinet Pharmacodyn 51(6):919–934. https://doi.org/10.1007/s10928-024-09940-9

Article  PubMed  PubMed Central  Google Scholar 

Bottino DC, Patel M, Kadakia E, Zhou J, Patel C, Neuwirth R, Iartchouk N, Brake R, Venkatakrishnan K, Chakravarty A (2019) Dose optimization for anticancer drug combinations: maximizing therapeutic index via clinical exposure-toxicity/preclinical exposure-efficacy modeling. Clin Cancer Res 25(22):6633–6643. https://doi.org/10.1158/1078-0432.CCR-18-3882

Article  PubMed  CAS  Google Scholar 

Elharrar X, Barbolosi D, Ciccolini J, Meille C, Faivre C, Lacarelle B, Andre N, Barlesi F (2016) A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. BMC Cancer 16:278. https://doi.org/10.1186/s12885-016-2308-z

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kobuchi S, Ito Y (2020) Application of pharmacometrics of 5-fluorouracil to personalized medicine: a tool for predicting pharmacokinetic-pharmacodynamic/toxicodynamic responses. Anticancer Res 40(12):6585–6597. https://doi.org/10.21873/anticanres.14683

Article  PubMed  CAS  Google Scholar 

Kobuchi S, Morita A, Jonan S, Amagase K, Ito Y (2024) Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule. Cancer Chemother Pharmacol 93(4):365–379. https://doi.org/10.1007/s00280-023-04625-5

Article  PubMed  CAS  Google Scholar 

Kweon S, Jeong YS, Chung SW, Lee H, Lee HK, Park SJ, Choi JU, Park J, Chung SJ, Byun Y (2022) Metronomic dose-finding approach in oral chemotherapy by experimentally-driven integrative mathematical modeling. Biomaterials 286:121584. https://doi.org/10.1016/j.biomaterials.2022.121584

Article  PubMed  CAS  Google Scholar 

Zhu J, Liu R, Jiang Z, Wang P, Yao Y, Shen Z (2015) Optimization of drug regimen in chemotherapy based on semi-mechanistic model for myelosuppression. J Biomed Inform 57:20–27. https://doi.org/10.1016/j.jbi.2015.06.021

Article  PubMed  Google Scholar 

Wick W, Platten M, Weller M (2009) New (alternative) Temozolomide regimens for the treatment of glioma. Neuro Oncol 11(1):69–79. https://doi.org/10.1215/15228517-2008-078

Article  PubMed  PubMed Central  CAS  Google Scholar 

Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20(24):4713–4721. https://doi.org/10.1200/JCO.2002.02.140

Article  PubMed  Google Scholar 

Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J (2020) PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 19(1):107. https://doi.org/10.1186/s12943-020-01227-0

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rose M, Burgess JT, O’Byrne K, Richard DJ, Bolderson E (2020) PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol 8:564601. https://doi.org/10.3389/fcell.2020.564601

Article  PubMed  PubMed Central  Google Scholar 

West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE (2019) Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: a retrospective matched cohort study. Cancer Med 8(12):5609–5618. https://doi.org/10.1002/cam4.2471

Article  PubMed  PubMed Central  CAS  Google Scholar 

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216. https://doi.org/10.1093/jnci/92.3.205

Article  PubMed  CAS  Google Scholar